Placeholder Banner

Diverse #BIO2017 Super Sessions Cover Trump, Manufacturing, and the Future

May 3, 2017
Announced this week, BIO 2017’s Super Sessions offer compelling, topical and relevant discussions on topics ranging from what manufacturing strategy is best for producing new drugs to how Washington and the Trump administration may impact investment and trade to a debate about affordable access to innovative medicines. Beginning on Monday afternoon, the five, 75 minute sessions will run every day of the Convention with the last one appropriately focused on looking to the future.

For a complete breakdown of this year’s Super Sessions, visit
Highlights include:

Monday, June 19
2:30 PM–3:45 PM
So Many Choices: What’s the Right Bio-manufacturing Strategy for Me?
This panel will review the formidable challenges and decisions facing biopharma executives preparing to launch a new product.
S. Ann Montgomery, Editor-in-Chief, BioProcess International
Som Chattopadhyay, VP, Supply Chain, Amgen
Steve Lam, Senior VP, Biologics, Patheon
Matt Ottmer, COO, Momenta
Johannes Roebers, CEO, Cilatus BioPharma AG

Tuesday, June 20
12:15 PM-1:30 PM
Dealmakers’ Intentions: 2017 Market Outlook
A highly distinguished panel of deal-makers will explore the impact market forces may have on pharmaceutical and biotech companies as they strive to make the next big deal.
Neel Patel, Managing Director, Commercial Strategy & Planning, inVentiv Health Consulting
Paul Biondi, Senior VP & Head, Business Development, Bristol-Myers Squibb
Doug Gioradano, Senior VP, Worldwide Business Development, Pfizer
Patrick Verheyen, Global Head, Janssen Business Development, Janssen Pharmaceutical Companies of Johnson & Johnson
Timothy P. Walbert Chairman, President and Chief Executive Officer, Horizon Pharma

Tuesday, June 20
12:15 PM-1:30 PM
Our Common Goal: Ensuring Access and Affordability of Innovative Medicines
This session will address the questions of how we ensure access and affordability of innovative medicines.
Ron Cohen, President and Chief Executive Officer, Acorda Therapeutics
Jeffrey Berkowitz, CEO, Optum International
Jeremy Levin, CEO & Chairman of the Board of Directors, Ovid Therapeutics
David Meeker, EVP and Head, Sanofi Genzyme
Steve Miller, SVP and Chief Medical Officer, Research and Clinical Sciences at Express Scripts, Inc.

Wednesday, June 21
12:15 PM-1:30 PM
The Trade and Investment Policies of the Trump Administration
This panel will focus on the Trump Administration’s trade and investment policies and their impact on the biotechnology industry.
Brian Pomper, Partner, Akin Gump Strauss Hauer & Feld LLP
Derek Scissors, Resident Scholar, American Enterprise Institute

Thursday, June 22
1:00 PM -2:15 PM
The Scientific American WorldView Super Session: Wrapping Up and Looking Forward
Join Scientific American Worldview and Nature Biotechnology for a discussion around the multiplicity of issues explored during the week's programs and get a snapshot of future trends.
Andrew Marshall, Chief Editor, Nature Biotechnology
Susan Peschin, President and CEO, Alliance for Aging Research